| Drug NDC: | 62185-0041 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Hormone Balance |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Salsolinol Hydrochloride, Dhea (dehydroepiandrosterone), 7-oxo-dehydroepiandrosterone-3b-acetate, Folliculinum, Oophorinum (suis), Cholesterinum, Progesterone, Testosterone, Cortisone Aceticum, Aldosterone, Androsterone, Follicle Stimulating Hormone |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Dr. Donna Restivo Dc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | 7-OXODEHYDROEPIANDROSTERONE 3-ACETATE - 8 [hp_X]/mL ALDOSTERONE - 12 [hp_C]/mL ANDROSTERONE - 12 [hp_C]/mL CHOLESTEROL - 8 [hp_X]/mL CORTISONE ACETATE - 12 [hp_X]/mL ESTRONE - 8 [hp_X]/mL FOLLITROPIN - 12 [hp_C]/mL PRASTERONE - 6 [hp_X]/mL PROGESTERONE - 8 [hp_X]/mL SALSOLINOL HYDROCHLORIDE, (+/-)- - 6 [hp_X]/mL Load more... SUS SCROFA OVARY - 8 [hp_X]/mL TESTOSTERONE - 8 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 30 Nov, 2018 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 08 Feb, 2024 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 08 May, 2026 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Dr. Donna Restivo DC |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000175838 M0009540 M0017672 N0000175601 N0000175824 N0000000146 M0001109 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | 84RQ0XOM11 4964P6T9RB C24W7J5D5R 97C5T2UQ7J 883WKN7W8X 2DI9HA706A 076WHW89TW 459AG36T1B 4G7DS2Q64Y 1C0F27WEAL Load more... S7YTV04R8O 3XMK78S47O |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class MOA: | Androgen Receptor Agonists [MoA] |
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. | |
| Pharmacologic Class EPC: | Gonadotropin [EPC] Progesterone [EPC] Androgen [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class CS: | Gonadotropins [CS] Progesterone [CS] Androstanes [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Androgen Receptor Agonists [MoA] Androgen [EPC] Androstanes [CS] Corticosteroid Hormone Receptor Agonists [MoA] Corticosteroid [EPC] Gonadotropin [EPC] Gonadotropins [CS] Progesterone [CS] Progesterone [EPC] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| DEA Schedule: | CIII |
| This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 62185-0041-1 | 30 mL in 1 BOTTLE, DROPPER (62185-0041-1) | 30 Nov, 2018 | 08 Feb, 2024 | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.